GH Research's inhaled psychedelic therapy GH001 has shown promise in a mid-stage trial in treatment-resistant depression (TRD ...
The small, Ireland-based company GH Research said its inhaled version of mebufotenin — a molecular cousin to psilocybin — was ...
Hosted on MSN14h
GHRS Stock Rallies 55% in a Week: Here's What You Should KnowShares of GH Research PLC GHRS have rallied 54.8% in a week after the company, on Feb. 3, 2025, announced that it has met the ...
In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...
Medicaid in Wisconsin has expanded to cover ketamine infusions as of Jan. 1, sparking conversations about the nuances in type ...
Oxford Mail on MSN5d
Oxford trial aims to tackle treatment-resistant depressionEarlier phases of the trial showed promising results, with a single 25mg dose of COMP360 psilocybin, combined with psychological support, significantly reducing depressive symptoms after three weeks, ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
The inhaled mebufotenin candidate, dubbed GH001, was evaluated in the midstage study of 81 patients with treatment-resistant depression. The 40 patients who received GH001 saw an average 15.2 point ...
Major strides for the company on two fronts – psychedelic therapies and treatment-resistant depression (TRD) – came in the ...
Inquirer on MSN2d
World’s first anti-depression nasal spray receives FDA approvalThe US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical ...
In people with treatment-resistant depression, investigational inhalable mebufotenin yielded a 15.5-point placebo-adjusted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback